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Abstract
Purpose—To estimate the rate of hypersensitivity reactions per 100,000 prescription dispensings 
of fluoroquinolones based on care rendered in a nationally-representative sample of US hospital 
emergency departments (ED).
Methods—We analyzed the frequency of fluoroquinolone-associated hypersensitivity reactions 
using the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event 
Surveillance system (2004–2010) in conjunction with US retail outpatient prescription data from 
IMS Health (2004–2010). We further categorized reaction severity into three subgroups (mild, 
moderate, severe).
Results—Based on 1,422 cases of fluoroquinolone-associated hypersensitivity reactions and 
national drug utilization projections, we estimated risk of hypersensitivity reactions for 
moxifloxacin, ciprofloxacin, and levofloxacin. The absolute risk of a fluoroquinolone-related 
hypersensitivity reaction of any severity was low (44.0 (95% CI 34.8–53.3) ED visits/100,000 
prescriptions; however, we identified a statistically significant difference in the relative risk (rate 
ratios) of seeking care in an ED attributed to moxifloxacin hypersensitivity compared to either 
levofloxacin or ciprofloxacin. For all reaction severities, the estimated ED visits/100,000 
prescriptions were 141.3 (95% CI 99.9–182.7) for moxifloxacin, 40.8 (95% CI 31.5–50.0) for 
levofloxacin, and 26.3 (95% CI 20.8–31.9) for ciprofloxacin. When the rates were stratified by 
reaction severity category (mild or moderate-severe), moxifloxacin continued to be implicated in 
more ED visits per 100,000 prescriptions dispensed than either levofloxacin or ciprofloxacin.
Conclusion—Fluoroquinolones may cause hypersensitivity reactions requiring care in an ED, 
and relative to use, the rate of moxifloxacin-related hypersensitivity reactions is higher than 
comparator fluoroquinolones.
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Introduction
Fluoroquinolones are an important and widely used class of antimicrobials in contemporary 
medical practice in the United States (US). The US Food and Drug Administration has 
approved six currently marketed, oral fluoroquinolones (ciprofloxacin, levofloxacin, 
moxifloxacin, gemifloxacin, norfloxacin, ofloxacin). Although fluoroquinolones have a 
favorable safety profile relative to their effectiveness, tendinopathy, exacerbation of 
myasthenia gravis, central and peripheral nervous system toxicities, QT interval 
prolongation resulting in torsade de pointes, Clostridium difficile-associated colitis, and 
hypersensitivity reactions, including anaphylaxis, are important safety concerns.
Fluoroquinolones induce hypersensitivity reactions via IgE mediated pathways and delayed 
T-cell mediated responses.1 Safety information in FDA approved fluoroquinolone labeling 
warns prescribers that serious and occasionally fatal hypersensitivity or anaphylactic 
reactions have been reported in patients receiving fluoroquinolone therapy. Among non-beta 
lactam antimicrobials, fluoroquinolones exhibited the highest frequency of hypersensitivity 
reactions during the past decade.2 It is not clear whether expanded use of fluoroquinolones 
or increased immunogenicity to newer fluoroquinolones is responsible for this trend.
Published data suggests that the risk of a hypersensitivity reaction is not uniform across the 
fluoroquinolone class. An in vitro study,3 analyses of spontaneous reports4,5 and a recent 
retrospective analysis of patients attending an allergy clinic,6 implicate moxifloxacin 
frequently or more often compared to other fluoroquinolones in hypersensitivity reactions. 
Johannes et al, in contrast, expanded on these studies by estimating the incidence of serious 
allergic reactions to fluoroquinolones using administrative claims data and determined that 
allergic diagnoses rates were similar for moxifloxacin and comparator fluoroquinolones.7 
Although most of the studies cited above implicate moxifloxacin more often than other 
fluoroquinolones, the data are largely based either on laboratory investigations, non-
randomized samples of convenience, or voluntarily submitted adverse drug event reports. 
Spontaneous adverse event reporting is prone to selection bias and is not amenable to 
providing estimates of incidence or comparative risks within a drug class, because the 
numerator and denominator cannot be reliably estimated.
Considering the conflicting analyses described above, the objective of this work was to 
estimate the rate of hypersensitivity reactions attributed to fluoroquinolones based on 
national public health surveillance data. We analyzed the frequency of fluoroquinolone-
related hypersensitivity reactions based on care rendered in a nationally-representative 
sample of US hospital emergency departments (ED) using dispensed prescriptions to 
estimate drug exposure.
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National estimates of ED visits were made using the National Electronic Injury Surveillance 
System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) system from 
January 1, 2004 through December 31, 2010. NEISS-CADES is a national public health 
surveillance system and has been previously described.8 Briefly, NEISS-CADES collects 
data from a nationally representative, stratified probability sample of 63 participating 
hospitals located within the United States or its territories, which have a minimum of six 
beds and a 24 hour ED. Trained coders at each hospital review the clinical records of each 
ED visit to identify physician-diagnosed drug related adverse events, reporting up to two 
implicated medications, select patient demographics, physician clinical diagnoses, testing, 
treatments, and brief narratives describing the visit, which are coded at the Centers for 
Disease Control and Prevention (CDC) using Medical Dictionary for Regulatory Activities 
(MedDRA) preferred terms. NEISS-CADES entries are de-identified data used to conduct 
public health surveillance and, therefore, are exempt from investigational review board 
oversight.
We queried NEISS-CADES for cases in which any one of the current US marketed 
fluoroquinolones was implicated in a hypersensitivity reaction requiring evaluation in an 
ED. We defined a case as any ED encounter attributed to a hypersensitivity reaction from a 
single orally administered fluoroquinolone based on the reported physician diagnosis and 
narrative description without additional reviewer imputation. Cases reporting known 
exposure to an otic, ophthalmic or an intravenous dosage formulation were excluded from 
analysis.
The primary author (SCJ) conducted an unblinded review and categorized each ED visit 
report by severity of the adverse reaction (e.g. mild, moderate or severe). A mild 
hypersensitivity reaction was defined as any self-limiting, non-anaphylactic adverse event, 
most typically rash, which did not result in hospital admission and required only minimum 
medical intervention aimed to relieve temporary discomfort. Moderate reactions were 
defined as those with signs and symptoms consistent with anaphylaxis such as dyspnea, 
tachycardia or chest pain, or extensive or desquamating skin reactions, or facial or laryngeal 
edema that did not result in hospitalization. Severe reactions referred to anaphylaxis which 
required hospital admission or observation in the ED for an extended period of time before 
discharge. After reviewing each case, we chose to combine moderate and severe reactions 
into one category for analysis. We did this because there were few severe reactions which 
substantially reduced the statistical power to detect differences between the drugs studied for 
severe reactions alone and the only substantive difference between the categories was 
hospitalization.
National estimates of outpatient fluoroquinolone use were provided by IMS Health Vector 
One® National database. The Vector One® database measures retail dispensing of 
prescriptions or the frequency with which drugs move out of retail pharmacies to consumers 
via formal prescriptions from a sample of 59,000 retail pharmacies throughout the US. 
Using these data, we estimated the total number with 95% confidence intervals for 
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prescriptions dispensed throughout US outpatient retail pharmacies from January 1, 2004 
through December 31, 2010 for US marketed fluoroquinolones.
We calculated national estimates (with corresponding 95% confidence intervals) for the 
frequency of ED visits from the NEISS-CADES sample, using the SURVEYMEANS 
procedure in SAS (Cary NC) version 9.2 to account for sample weights and complex sample 
designs in the stratified probability sample. National estimates using this procedure were 
considered reliable if there were ≥20 cases from the sample on which that estimate was 
based, the national estimate was ≥1,200 cases and the coefficient of variation was <0.30.
To estimate rates of ED visits for fluoroquinolone hypersensitivity reactions relative to 
outpatient medication use, we divided the estimated number of ED visits by the estimated 
number of outpatient prescriptions dispensed. Calculation of the 95% confidence interval for 
each rate incorporated variance estimates for both numerator and denominator components 
of the corresponding rate estimate9,10 Because these components were calculated from 
separate surveillance systems, they were treated as independent (and, thus, as having zero 
covariance).
Rate ratios (RRs) were used to compare rates of ED visits for fluoroquinolone 
hypersensitivity reactions relative to outpatient medication use for each drug within the 
fluoroquinolone drug class, using the fluoroquinolone with the lowest rate as the reference 
group. The estimates and variance for the RRs incorporated the estimated variance of the 
numerator and denominator components of the RR.9 The component rate estimates were 
again assumed to be independent across patient populations.
Results
NEISS-CADES includes 1,659 cases of ED visits for a hypersensitivity reaction attributed to 
any fluoroquinolone between the years 2004–2010. We excluded cases with more than one 
implicated drug (n=187) and cases involving a suspect non-oral formulation (n=29). We also 
excluded cases relevant to gemifloxacin (n=12) and ofloxacin (n=9), because these sample 
sizes were insufficient to reliably project national estimates. No cases of norfloxacin-
associated hypersensitivity were retrieved from the database. After these exclusions, 1,422 
cases remained, composed of three suspect fluoroquinolones; ciprofloxacin (n=469), 
levofloxacin (n=505), and moxifloxacin (n=448). Figure 1 is a flow diagram of the case 
selection criteria used in this analysis.
The demographic and clinical characteristics of the case patients were comparable across the 
three fluoroquinolones (Table 1). Reaction severities were also proportionate across the 
fluoroquinolone subgroups with mild reactions occurring most frequently (63%) followed 
by moderate (31%) and severe (6%) reactions. Likewise there were similar proportions of 
cases with comparable concomitant medications per case for each fluoroquinolone 
evaluated, with roughly half of all cases not reporting any concomitant drug. The 
hypersensitivity reactions experienced by these patients rarely resulted in hospitalization 
(6%). Mortality is not a measured outcome in NEISS-CADES, so we were unable to use 
fatality as a surrogate indicator of reaction severity. Additionally, the dose, duration and 
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indication of the fluoroquinolone, and clinical details of the hypersensitivity reactions in this 
NEISS-CASES sample were infrequently reported.
National estimates of prescriptions dispensed (with corresponding 95% confidence intervals) 
for fluoroquinolones are provided in Table 2. Between 2004 and 2010, there were an 
estimated 236.9 (95% CI 236,882,377 – 236,954,618) million prescriptions dispensed for 
fluoroquinolones in the United States. In that time period, the most frequently dispensed 
fluoroquinolone prescription was ciprofloxacin, followed by levofloxacin and moxifloxacin. 
Approximately one-tenth of all fluoroquinolone prescriptions dispensed (10.3%) were for 
moxifloxacin.
Between 2004–2010, we estimated 102,684 (95% CI 81,026–124,342) ED visits occurred 
because of a hypersensitivity reaction of any severity that was attributed to either 
ciprofloxacin, levofloxacin or moxifloxacin (Table 3). We observed no statistically 
significant differences in the number of ED visits across the three fluoroquinolones when the 
data were either combined or stratified by reaction severity. However, a higher proportion 
met criteria for moderate to severe reactions for moxifloxacin and levofloxacin versus 
ciprofloxacin, although this difference was not significant.
We combined national estimates of ED visits for hypersensitivity reactions and the 
estimated number of prescriptions dispensed to compute the overall rates and rate ratios for 
ED visits per 100,000 prescriptions (Table 4). In pooling all hypersensitivity reactions 
regardless of severity, moxifloxacin [141.3 visits/100,000 prescriptions (95% CI 99.9–
182.7)] was associated with the highest rate of ED visits and this difference was statistically 
significant compared to both levofloxacin [40.8 visits/100,000 prescriptions (95% CI 31.5–
50.0)] and ciprofloxacin [26.3 visits/100,000 prescriptions (95% CI 20.8–31.9)]. The 
difference between levofloxacin and ciprofloxacin was not significant. The absolute risk of a 
fluoroquinolone-related hypersensitivity reaction of any severity was 44.0 (95% CI 34.8–
53.3) ED visits/100,000 prescriptions.
Across all severity categories, the rate ratios (relative risks) of hypersensitivity reaction 
requiring an ED visit for moxifloxacin was 3.5 (95% CI 2.2–4.7) and 5.4 (95% CI 3.4–7.3) 
times higher than with levofloxacin and ciprofloxacin, respectively (Table 4). When rates 
are stratified by reaction severity (mild or moderate-severe), the risk difference widens with 
moxifloxacin and levofloxacin approximately 7.4 (95% CI 4.4–10.4) and 2.0 (95% CI 1.3–
2.7) times more likely than ciprofloxacin to be implicated in a moderate-severe 
hypersensitivity reaction requiring treatment in an ED. Among mild reactions, moxifloxacin 
was associated with 4.5-fold (95% CI 2.6–6.4) more hypersensitivity reactions than 
ciprofloxacin. The difference between ciprofloxacin and levofloxacin for mild reactions was 
not significant.
Discussion
Using nationally representative samples of ED visits and outpatient prescriptions dispensing, 
we estimate the rate of ED visits for hypersensitivity attributed to ciprofloxacin, 
levofloxacin and moxifloxacin. Regardless of severity, the overall risk of hypersensitivity 
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reactions resulting in ED visits was low for all fluoroquinolones studied; however, 
moxifloxacin exhibited a significantly higher rate of hypersensitivity reactions per 100,000 
prescriptions dispensed across all severity categories compared with levofloxacin or 
ciprofloxacin.
Shehab et al.11 published a paper which provide context to the magnitude of 
fluoroquinolone-induced hypersensitivity compared to other antimicrobials. This group used 
NEISS-CADES data, and estimates of outpatient prescriptions using national medical 
surveys to compare the relative rates of mild or moderate-severe allergic reactions across 
various classes of antimicrobials. Based on these data, fluoroquinolones are less frequently 
implicated in ED visits for mild allergic reactions than penicillins, sulfonamides, or 
lincosamides. Although, the rate of moderate-severe allergic reactions for fluoroquinolones 
appears to be comparable to penicillin and cephalosporin beta-lactams, yet less than those 
attributed to sulfonamides.
Our findings are consistent with those of previously described published studies3–6 that have 
shown an enhanced risk of hypersensitivity associated with moxifloxacin use compared to 
other fluoroquinolones, but differ from the results of Johannes et al7 that indicated no 
difference across the fluoroquinolone class. While we observed a disproportionate number 
of ED visits for moxifloxacin-associated hypersensitivity reactions relative to dispensings, 
Johannes et al. observed no difference using administrative claims data. They determined 
that the incidence of any allergic diagnosis made in the hospital or ED was similar for 
moxifloxacin and comparators. While a strength of their study was its statistical power, 
enabled by a large sample size, limitations compared to the NEISS-CADES database may 
affect interpretability. First, Johannes et al. used administrative data (ICD-9 codes) to 
identify cases supported by medical record review of anaphylaxis cases only, which may not 
be sufficiently sensitive to identify true cases. All NEISS-CADES data is derived from chart 
review without reliance on administrative coding. Secondly, in the Johannes study, the 
source population was insured US residents concentrated in the Midwest and the Southeast, 
which may not adequately represent the entire US populace. Our sample is solely composed 
of persons who seek care in an US-based ED for hypersensitivity, which may represent a 
different demographic.
The methods employed in our analysis offer several additional strengths. First, NEISS-
CADES data are actively collected and are a nationally representative sample of US-based 
EDs which permit inferences about drug related adverse events in the entire US population 
seeking care in an ED. This level of statistical inference is not possible with a spontaneous 
surveillance system, similar to that employed by Sachs4 to compute reporting rates of 
fluoroquinolone-induced allergic reactions, because there is uncertainty with respect to 
underreporting of adverse events. Second, each case was subjected to a detailed review to 
categorize the severity of the hypersensitivity reaction using our case definition. This 
categorization minimized potential misclassification of cases that may occur with automated 
methods, such as categorizing cases based on MedDRA coding alone. The most frequent 
MedDRA preferred terms reported for each severity category across the fluoroquinolones 
were consistent for mild reactions (‘rash’, ‘drug hypersensitivity’ and ‘urticaria’) and for 
moderate-severe reactions (‘dyspnoea’, ‘drug hypersensitivity’ and ‘swelling face’). This 
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provides a level of reassurance that we categorized cases appropriately without systemic 
bias. Although attribution can be biased, we believe an additional strength of using NEISS-
CADES as a data source is that each case includes physician attribution, which in this 
surveillance system, has been demonstrated to have a high positive predictive value (92%),8 
based on a sample of 29 reports of all types (allergic reactions and others). Additionally, 
because the physicians who make diagnoses in NEISS-CADES data collection hospitals are 
not part of the data extraction process, they are acting as caregivers and not as researchers in 
a surveillance system and are therefore, less likely to bias the data toward any one drug.
There are also several limitations that should be considered when interpreting these data. 
The classification of hypersensitivity severity for each fluoroquinolone was assigned in an 
unblinded review, as the suspect drug was readily available in each report. However, to 
minimize this potential bias, we applied an a priori case definition to objectively categorize 
each case. Additionally, our rate estimates are crude measures that have not been statistically 
adjusted. Even though the baseline patient characteristics stratified by drug (Table 1) were 
comparable, because these data are not randomized, we cannot exclude the possibility of 
confounding. However, the sample of NEISS-CADES cases are prospectively collected, in 
the absence of a research hypothesis, which should reduce the chance of selection bias 
preferentially implicating a given fluoroquinolone. Information bias is also a potential 
concern because available drug information in the literature could influence the diagnosing 
physician to selectively attribute more hypersensitivity cases to moxifloxacin. We also used 
prescriptions dispensed as the basis of fluoroquinolone exposure, although, we have no 
means to ascertain whether prescriptions dispensed proportionately correspond to patient 
exposure. However, there is no reason to believe there is differential misclassification of 
these exposures across the fluoroquinolones. Although these data are derived from two 
nationally representative samples of ED visits and outpatient prescriptions dispensed, we 
cannot exclude the possibility of sampling error, whereby prescription patterns for 
moxifloxacin in the NEISS-CADES sample could be disproportionately higher than those of 
the IMS Health population. However, to minimize this chance of this error, we incorporated 
estimates of variability using 95% confidence intervals in our rate estimates that make this 
possibility unlikely.
The methods employed in this work do not fully capture all fluoroquinolone-induced 
hypersensitivity reactions. Although, this work likely accurately measures the most serious 
reactions attributed to fluoroquinolones requiring an evaluation by an emergency physician, 
it does not capture events that were not diagnosed by an ED physician or were managed in a 
setting outside of the ED (e.g. medical offices, clinics or self-treatment). Arguably, the 
morbidity attributed to hypersensitivity reactions is likely higher than what we estimate.
Differential risk of hypersensitivity reactions following fluoroquinolone exposure may be 
plausible based on laboratory investigations, published case reports and differences in the 
chemical structures of the fluoroquinolones. All fluoroquinolones exhibit some form of 
cross reactivity in hypersensitivity reactions owing to the 4-oxo-1,4,-dihydroquinoline ring 
common to these drugs,12 but the degree of this cross reactivity is inconsistent across the 
drug class. Several case reports have shown that one patient may develop a hypersensitivity 
reaction to moxifloxacin, only to be re-challenged with a different fluoroquinolone without 
Jones et al. Page 7













sequelae, 13,14,15 suggesting that substituents other than the fluoroquinolone ring nucleus are 
potential hypersensitivity determinants. Data reported in the literature support the 
importance of the moieties situated in positions N-1, 7 and 8 of the quinolone nucleus in 
immungenicity.1,6,13 While speculative, select substituents could bind to protein with 
varying degrees of affinity, to elicit an immune response to a fluoroquinolone-protein 
complex at different rates.
Fluoroquinolones are implicated in ED visits for hypersensitivity in the United States, albeit 
the risk appears to be low. Even though the absolute risk of a hypersensitivity reaction 
(regardless of severity) requiring an ED visit was low, the relative differences in risk, 
implicating moxifloxacin more often in these reactions than levofloxacin or ciprofloxacin 
could be important. Considering the high volume of prescriptions dispensed for 
moxifloxacin, even small absolute risks could substantially contribute to ED visits, and 
switching large populations of patients to moxifloxacin-based regimens would be expected 
to increase hypersensitivity-associated ED visits.
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• Fluoroquinolone-associated hypersensitivity reactions requiring treatment in an 
emergency department are rare in the United States.
• The comparative rate of emergency department visits for moxifloxacin-
associated hypersensitivity reactions was higher than that for ciprofloxacin and 
levofloxacin, and the difference was statistically significant.
• The risk of hypersensitivity reaction is comparable for ciprofloxacin and 
levofloxacin.
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Flow Diagram of NEISS-CADES Case Selection
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Table 1
Cases of Emergency Department Visits for Hypersensitivity Reactions to Fluroquinolones, National Electronic 
Injury Surveillance System-Cooperative Adverse Drug Event Surveillance, 2004–2010









 Mean (years) ±SD 47±19.5 49±18.4 49±15.8 39±19.6
 (Range)b (1–98) (13–93) (12–90) (7–80)
Gender
 Male 112 (24%) 154 (30%) 104 (23%) 8 (44%)
 Female 357 (76%) 351 (70%) 344 (77%) 10 (56%)
Race
 White 242 (52%) 309 (61%) 274 (61%) 10 (56%)
 Black 59 (13%) 49 (10%) 21 (5%) 2 (11%)
 Asian 5 (1%) 0 (0%) 2 (<1%) 0 (0%)
 Not Stated 125 (27%) 115 (23%) 135 (30%) 5 (28%)
 Other 38 (8%) 32 (6%) 16 (4%) 1 (6%)
Allergic Reaction Category
 Mild 321 (68%) 311 (62%) 265 (59%) 14 (78%)
 Moderate 123 (26%) 158 (31%) 155 (35%) 4 (22%)
 Severe 25 (5%) 36 (7%) 28 (6%) 0 (0%)
Concomitant Medications per Case
 None Listed 241 (51%) 261 (52%) 218 (49%) 9 (50%)
 1–3 medications 133 (28%) 153 (30%) 140 (31%) 7(39%)
 4–6 medications 64 (14%) 57 (11%) 60 (13%) 2 (11%)
 ≥ 7 medications 31 (7%) 34 (7%) 30 (7%) 0 (%)
Disposition
 Treated and Released 429 (91%) 459 (91%) 411 (92%) 17 (94%)
 Admitted 24 (5%) 32 (6%) 24 (5%) 0 (0%)
 LAMAc 12 (3%) 5 (1%) 6 (1%) 1 (6%)
 Observation in ED 4 (1%) 6 (1%) 6 (1%) 0 (0%)
 Transferred 0 (0%) 3 (1%) 1 (<1%) 0 (0%)
a
Gemifloxacin (n=12) and Ofloxacin (n=6),
b
There were a total of nine pediatric (<16 years) cases in the dataset distributed as ciprofloxacin (n=5), levofloxacin (n=1), moxifloxacin (n=1), 
gemifloxacin (n=1), and ofloxacin (n=1).
c
LAMA=left against medical advice
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